• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Respir J . High flow nasal cannula for acute respiratory failure due to COVID-19 in patients with a 'do-not-intubate' order: A survival analysi

tetano

Editor, Senior Moderator
Clin Respir J


. 2022 Dec 30.
doi: 10.1111/crj.13573. Online ahead of print.
High flow nasal cannula for acute respiratory failure due to COVID-19 in patients with a 'do-not-intubate' order: A survival analysis


Illaa Smesseim[SUP] 1 [/SUP], Kirsten Mooij-Kalverda[SUP] 1 [/SUP], Lisa Hessels[SUP] 2 [/SUP], Daniel A Korevaar[SUP] 1 [/SUP], Burak Atasever[SUP] 3 [/SUP], Hjalmar de Graaff[SUP] 4 [/SUP], Abraham Goorhuis[SUP] 5 [/SUP], Esther Nossent[SUP] 1 6 [/SUP], Lieuwe Bos[SUP] 1 7 [/SUP], Peter Bonta[SUP] 1 [/SUP]; Amsterdam UMC HFNC study group:; Joost van den Aardweg[SUP] 1 [/SUP], Wim Boersma[SUP] 2 [/SUP], Ivo van der Lee[SUP] 3 [/SUP], Herre J Reesink[SUP] 4 [/SUP]



Affiliations

Abstract

Introduction: High flow nasal cannula (HFNC) reduces the need for intubation in patients with hypoxaemic acute respiratory failure (ARF), but its added value in patients with severe coronavirus disease 2019 (COVID-19) and a do-not-intubate (DNI) order is unknown. We aimed to assess (variables associated with) survival in these patients.
Materials and methods: We described a multicentre retrospective observational cohort study in five hospitals in the Netherlands and assessed the survival in COVID-19 patients with severe acute respiratory failure and a DNI order who were treated with high flow nasal cannula and which variables associated with survival.
Results and discussion: One-third of patients survived after 30 days. Survival was 43.9% in the subgroup of patients with a good WHO performance status and only 16.1% in patients with a poor WHO performance status. Patients who were admitted to the hospital for a longer period prior to HFNC initiation were less likely to survive. HFNC resulted in an increase in ROX values, reflective of improved oxygenation and/or decreased respiratory rate.
Conclusion: Our data suggest that a trial of HFNC could be considered to increase chances of survival in patients with ARF due to COVID-19 pneumonitis and a DNI order, especially in those with a good WHO performance status.

Keywords: ARDS; covid-19; dni-order; do-not-intubate order; hfnc.
 
Back
Top Bottom